Sekar Kathiresan
CEO
Sekar Kathiresan is a cardiologist and the CEO of Verve Therapeutics, a subsidiary of Eli Lilly. He led the recent groundbreaking study on a genetic editing treatment that significantly reduces LDL cholesterol levels, motivated by personal family health experiences with heart disease.
Global Media Ratings
Dominance
0.00%
Persistence
0 wks
Reach
0
Power
0$
Sentiment
0.00
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Brazil:
Sekar Kathiresan is the CEO of Verve Therapeutics and led the study on the genetic editing treatment.
8
John H P Alexander
Eric Rubin
J Michael Gaziano
Daniel Skovronsky
Kristy Faulkner
Erica Spatz
Alice Thomas
O Globo: Prevenção definitiva do colesterol? Cientistas mostram que pode ser possível